Avant Technologies Completes Rebranding with Name Change to Avaí Bio and Launch of New Website

Core Perspective - The company has completed its rebranding from Avant Technologies to Avaà Bio, reflecting a focused commitment to developing cell-based therapies for diabetes and age-related disorders [1] Company Overview - Avaà Bio, Inc. is an emerging biotechnology company that specializes in genetically modified cell lines and aims to develop innovative cell-based therapies through joint ventures and licensing agreements [1] Rebranding Details - The rebranding to Avaà Bio is effective as of February 11, 2026, and the company's stock will continue to trade under the ticker symbol AVAI on OTC Markets [1] - The new corporate identity aims to align with the company's core operations in sourcing, developing, and protecting advanced cellular therapies [1] Pipeline Highlights - Diabetes Development Program: Focuses on genetically modified cell lines designed to produce, store, and secrete insulin, combined with proprietary encapsulation for immune protection, targeting type 1 and insulin-dependent type 2 diabetes [1] - Klotho Development Program: Aims to advance a "longevity protein" overexpression cell line to address age-related decline and broader anti-aging applications [1] - The company has formed strategic collaborations, including Insulinova for the diabetes program and Klothonova for the Klotho program, to enhance clinical translation through joint research and licensing [1] Strategic Vision - The rebranding is seen as a pivotal moment in the company's evolution, positioning it to attract high-quality partnerships, accelerate research and development, and bring innovative treatments closer to patients [1]